Shanghai Dismisses Two Researchers After Child’s Death in Experimental Gene-Editing Treatment

Photo: Adam Bezer / Unsplash

Investigators found failures in safety review, ethics oversight and risk disclosure, plus undisclosed payments, but no fabricated data.

Background

On Nov. 13, a Shanghai investigation team released findings on a child's death after an experimental gene-editing treatment at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine [1][3]. Caixin reported that the patient was a six-year-old girl [2]. Sixth Tone reported that she had Snijders Blok-Campeau syndrome, a rare neurodevelopmental disorder with no effective treatment [1].

In July 2023, the family approached Qiu Zilong, deputy director of the medical school's Songjiang Research Institute, about a customized therapy [1]. The treatment used a base editor, a CRISPR-derived tool that changes a single DNA letter. Live Science reported that modified viruses carrying the editor were injected into the child's spinal fluid and were intended to reach the brain [5]. She received the injection on March 24, 2025, and died seven days later [1]. At an emergency review on April 2, the hospital ethics committee attributed the death to thrombotic microangiopathy, a known complication of gene therapy, and ordered the study terminated [1].

The death was not made public at the time. In February 2026, Qiu's team published preclinical work in Nature on correcting the relevant DNA error in mice, with monkey experiments suggesting potential human use [1][2]. The paper did not mention the death [1]. A joint investigation by Science and Retraction Watch revealed the case in late July [3][6]. It also reported that the paper left out animal safety findings: four treated monkeys developed moderate to severe liver damage, and one also had kidney damage [1][5].

What Investigators Found

Investigators found problems at several stages [1]:

  • Safety data. Qiu's team did not promptly share a primate safety report with the clinical study's lead investigator [1]. Caixin reported that this report showed liver damage [2].

  • Ethics review. The hospital ethics committee approved the study even though toxicology and safety evidence was insufficient. It proceeded without materials it had requested [1][3].

  • Consent. The consent form warned of serious complications but did not prominently state the risk of death [1][3].

  • The paper. Investigators found no data fabrication in the Nature paper [1][3][4]. They did find that the methods described differed from those used, and that data from one experimental batch were presented separately without explanation [1].

  • Money. The family contributed about 5.337 million yuan toward the research [4]. Separately, researchers received about 1.06 million yuan in money and gifts from the family [1]. The paper did not disclose financial conflicts involving four researchers. Qiu received about 100,000 yuan in expensive liquor and electronics. Yang Kan, an associate researcher at Xinhua Hospital and the paper's first and corresponding author, received 900,000 yuan and expensive liquor. Two other team members received 30,000 yuan each [1]. These have since been returned or surrendered [1].

Sanctions and Responses

Qiu and Yang were dismissed, barred for five years from science and technology programs and awards, and entered into a national database of serious research-integrity violations [1][2][4]. Five senior hospital officials were disciplined [4]. The clinical study's lead investigator, surnamed Yu, was removed as head of the hospital's research department, demoted and barred for five years from promotion, programs, awards and recruiting graduate students [1]. An official surnamed Shi was removed as head of the ethics committee office and demoted. Other officials received disciplinary sanctions, and Xinhua Hospital received an administrative penalty whose details were not disclosed [1].

None of the reports reviewed for this article included a response from Qiu or Yang to the findings. In July, Qiu, the university and the hospital did not respond to Science's requests for comment [5]. At that time, the medical school said it would set up a special task force to investigate [6].

Nature added an editor's note on July 29, 2026. The note alerts readers that concerns have been raised about the article, "including with the data presented" [6]. VBN could not access the paper's page to confirm whether the journal has taken any further action since the Shanghai findings.

What Comes Next

The Shanghai Municipal Health Commission said it would launch special inspections of clinical research involving emerging biomedical technologies [1].

The case has sharpened scrutiny of investigator-initiated trials, which have grown rapidly in China. Deaths have also emerged in trials of two other companies' therapies, and in August two US lawmakers cited them in urging the FDA to scrutinize China-origin data [3]. New Chinese rules that took effect in May limit such trials to top-tier hospitals and set tougher penalties [3].

Whether Nature corrects or retracts the paper remains open. The larger question is how a bespoke experiment on a child cleared ethics review on safety evidence that investigators themselves judged insufficient.

This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.

References

  1. Jiang Xinyi. Shanghai Sacks Two Scientists Over Child's Death in Gene Trial. Sixth Tone. Nov. 16, 2026. https://www.sixthtone.com/news/1019274

  2. Cui Xiaotian. Shanghai Fires Gene-Editing Researcher After Child's Death. Caixin Global. Nov. 14, 2026. https://www.caixinglobal.com/2026-11-14/shanghai-fires-gene-editing-researcher-after-childs-death-102504707.html

  3. Bloomberg (via The Star). China fires researchers after child dies in gene-editing trial. The Star. Nov. 14, 2026. https://www.thestar.com.my/aseanplus/aseanplus-news/2026/11/14/china-fires-researchers-after-child-dies-in-gene-editing-trial

  4. Faisal Mahmud. China dismisses researchers, sanctions hospital officials over gene therapy scandal. Anadolu Agency. Nov. 13, 2026. https://www.aa.com.tr/en/asia-pacific/china-dismisses-researchers-sanctions-hospital-officials-over-gene-therapy-scandal/4124020

  5. Nicoletta Lanese. 6-year-old in China dies after experimental treatment, investigation finds, raising questions about the country's gene therapy regulations. Live Science. July 24, 2026. https://livescience.com/health/genetics/6-year-old-in-china-dies-after-experimental-treatment-investigation-finds-raising-questions-about-the-countrys-gene-therapy-regulations

  6. Retraction Watch Staff. Journal, university investigations launched into gene-editing death following Science-Retraction Watch reporting. Retraction Watch. July 30, 2026. https://retractionwatch.com/2026/07/30/nature-university-china-investigations-gene-editing-death-science/

Emma Nguyễn

While you argue with patients over TikTok liver detoxes, I investigate the the biology behind the sensationalism. At Culture Desk Rx, documenting where clinical reality collides with the wellness industry is my passion. I left Silicon Valley for Austin, Texas, where I willingly infiltrate unhinged wellness retreats to see if a "higher consciousness" actually exists, or if it's just severe dehydration. I also write the occasional joke. Deal with it.

I write about the parts of medicine nobody puts in the brochure. Who actually staffs the hospital, and who gets left out. Why safety-net hospitals run on doctors trained overseas, and what those doctors give up to work here. Who gets into medical school, and who decides.

Tell me what the medical establishment is ignoring, or just send me the wildest pseudo-science your patients have tried this week. My inbox is open.

Previous
Previous

Ethics Waivers Let Kennedy's Preventive Care Panel Keep Drug Stocks and Private Practices

Next
Next

Boston Scientific’s Obsidio Embolic Posts Clean 30-Day Results in Company-Sponsored Registry